First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
Forty-two healthy women volunteered to have blood samples drawn at 2, 4, 8, 24, 48, and 168 h (7 days) following placement of levonorgestrel-releasing rod (LNG rod) or of Norplant capsule implants to permit measurement of drug concentrations. Three clinics recruited 10 women each, half of whom used each type of implant. Twelve additional subjects were later enrolled at one site to provide greater detail for the capsule implants. Throughout the week, women with Norplant implants had apparently higher mean drug concentrations than did women with LNG rod implants, but the differences were significant only in the first 48 h after placement (p < 0.05). Maximum levels for capsule implants were found at the 24-h sample (mean, 1358 to 1474 pg/mL) and for the LNG rod implants at 48 h (772 pg/mL). Body weight was negatively correlated with levonorgestrel concentrations at all times (p < 0.05). For several sampling times, differences between clinics in mean concentrations were statistically significant after weight adjustment. Despite differences by implant type, weight, or clinic location, drug concentrations compatible with contraceptive effect were attained within 24 h in users of LNG rod or of Norplant implants, insofar as all women had levonorgestrel concentrations above 250 pg/mL at the 24-h sample.
Sivin
I
I
Center for Biomedical Research, Population Council, New York, NY 10021, USA.
Lähteenmäki
P
P
Mishell
D R
DR
Alvarez
F
F
Diaz
S
S
Ranta
S
S
Grozinger
C
C
Lacarra
M
M
Brache
V
V
Pavez
M
M
Nash
H
H
Stern
J
J
D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D004343:Drug Implants; D005260:Female; D006801:Humans; D007700:Kinetics; D016912:Levonorgestrel / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics
D003271:Contraceptive Agents, Female; D004343:Drug Implants; D016912:Levonorgestrel